Physician profile
Varda Singhal
NPI 1295176790
$5,453.27
in general payments reported to CMS, 2019-2025
32 companies · $287 in 2025
The $287 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $1,398 · 2021: $1,777 · 2022: $958 · 2023: $733 · 2024: $301 · 2025: $287.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,270 · Travel and Lodging: $49.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,270.48 |
| Travel and Lodging | $49.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $538.36 | 2020-2023 | Lifevest |
| Novartis Pharmaceuticals Corporation | $431.16 | 2020-2025 | |
| Kowa Pharmaceuticals America, INC. | $390.54 | 2021-2022 | |
| Abbott Laboratories | $356.52 | 2020-2025 | Cardiomems, Optis, Thoratec Heartmate 3 Lvas Implant Kit |
| Janssen Pharmaceuticals, INC | $326.11 | 2020-2022 | |
| Amgen INC. | $304.62 | 2020-2023 | Repatha |
| Boston Scientific Corporation | $299.45 | 2020-2023 | Watchman Access System, Watchman |
| Astrazeneca Pharmaceuticals Lp | $272.98 | 2020-2022 | |
| Chiesi USA, INC. | $259.65 | 2020-2025 | Kengreal, Cleviprex |
| Philips North America LLC | $242.98 | 2020 | |
| Abiomed | $233.71 | 2020 | |
| Actelion Pharmaceuticals US, INC. | $187.49 | 2021-2023 | Uptravi, Opsumit |
| Shockwave Medical, INC | $181.83 | 2023-2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Cardiovascular Systems INC. | $179.41 | 2020 | |
| Teleflex LLC | $176.71 | 2025 | Guideliner |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $163.90 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $155.29 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $115.90 | 2021-2023 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $94.50 | 2022-2023 | Camzyos |
| Kiniksa Pharmaceuticals, Ltd. | $93.86 | 2021-2022 | |
| Amarin Pharma, INC. | $64.15 | 2020-2021 | |
| Alexion Pharmaceuticals, INC. | $60.71 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $59.83 | 2021-2023 | |
| Daiichi Sankyo INC. | $56.08 | 2021-2023 | Injectafer |
| Novo Nordisk INC | $48.47 | 2021-2023 | Rybelsus, Ozempic |
| Esperion Therapeutics, INC. | $44.14 | 2021 | |
| Csl Behring | $22.78 | 2020 | |
| Cmp Pharma, INC. | $21.66 | 2022 | |
| Pfizer INC. | $20.84 | 2025 | |
| Elutia, INC. | $20.17 | 2021 | |
| Lexicon Pharmaceuticals, INC. | $14.76 | 2023 | Inpefa |
| Bardy Diagnostics, INC. | $14.71 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Varda Singhal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.